Related Experiment Video

Updated: Aug 7, 2026

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
04:41

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40)

J J Miguel-Hidalgo1, X A Alvarez, R Cacabelos

  • 1Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, USA. jmiguel-hidalgo@psyhiatry.umsmed.edu

Brain Research
|December 7, 2002
PubMed

Insights

Memantine, a treatment for Alzheimer's disease (AD), protected rats against beta-amyloid-induced neurotoxicity and cognitive impairment. This suggests memantine

Area of Science:

  • Neuroscience
  • Pharmacology
  • Alzheimer's Disease Research

Background:

  • Alzheimer's disease (AD) involves neuronal loss and cognitive decline, potentially worsened by beta-amyloid (Aβ)-induced excitotoxicity.
  • Memantine, an NMDA receptor antagonist, is in clinical development for AD and shows neuroprotective effects in preclinical models.

Purpose of the Study:

  • To investigate the neuroprotective effects of memantine against Aβ(1-40)-induced neurotoxicity and learning deficits in a rat model.
  • To assess memantine's impact on neuronal degeneration, apoptosis, and glial activation in the hippocampus.

Main Methods:

  • Adult Sprague-Dawley rats received subcutaneous memantine or vehicle via osmotic pump for 9 days.
  • Intrahippocampal injections of Aβ(1-40) were administered after 2 days of treatment.
  • Neuronal degeneration, apoptosis, glial activation (GFAP), and cognitive function (spatial discrimination) were evaluated.

Main Results:

  • Aβ(1-40) injection induced significant neuronal loss in the CA1 region, apoptosis, and glial activation.
  • Memantine treatment significantly reduced neuronal degeneration, pyknotic nuclei, and GFAP immunostaining compared to vehicle controls.
  • No significant differences in psychomotor activity were observed between groups.

Conclusions:

  • Memantine demonstrates significant neuroprotective effects against Aβ(1-40)-induced neuronal damage and apoptosis in the rat hippocampus.
  • These findings support the therapeutic potential of memantine in mitigating beta-amyloid-related neurotoxicity in Alzheimer's disease.
  • Therapeutically relevant concentrations of memantine may offer protection against excitotoxicity contributing to AD pathogenesis.

More Related Videos

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits08:01

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...